Prox1 Suppresses Proliferation and Drug Resistance of Retinoblastoma Cells via Targeting Notch1
Retinoblastoma (RB) is a prevalent type of eye cancer in youngsters. Prospero homeobox 1 (Prox1) is a homeobox transcriptional repressor and downstream target of the proneural gene that is relevant in lymphatic, hepatocyte, pancreatic, heart, lens, retinal, and cancer cells. The goal of this study was to investigate the role of Prox1 in RB cell proliferation and drug resistance, as well as to explore the underlying Notch1 mechanism.
Human RB cell lines (SO-RB50 and Y79) and a primary human retinal microvascular endothelial cell line (ACBRI-181) were used in this study. The expression of Prox1 and Notch1 mRNA and protein in RB cells was detected using quantitative real time-polymerase chain reaction (RT-qPCR) and Western blotting. Cell proliferation was assessed after Prox1 overexpression using the Cell Counting Kit-8 and the MTS assay. Drug-resistant cell lines (SO-RB50/vincristine) were generated and treated with Prox1 to investigate the role of Prox1 in drug resistance. We employed pcDNA-Notch1 to overexpress Notch1 to confirm the role of Notch1 in the protective function of Prox1. Finally, a xenograft model was constructed to assess the effect of Prox1 on RB in vivo.
Prox1 was significantly downregulated in RB cells. Overexpression of Prox1 effectively decreased RB cell growth while increasing the sensitivity of drug-resistant cells to vincristine. Notch1 was involved in Prox1’s regulatory effects. Notch1 was identified as a target gene of Prox1, which was found to be upregulated in RB cells and repressed by increased Prox1 expression. When pcDNA-Notch1 was transfected, the effect of Prox1 overexpression on RB was removed. Furthermore, by downregulating Notch1, Prox1 overexpression slowed tumor development and increased vincristine sensitivity in vivo.
These data show that Prox1 decreased RB cell proliferation and drug resistance by targeting Notch1, implying that Prox1 could be a potential therapeutic target for RB.
Prox1 / Notch1 / retinoblastoma cells / proliferation / drug resistance
[1] | Ademola-Popoola DS, Opocher E, Reddy MA. Contemporary management of retinoblastoma in the context of a low-resource country. Niger Postgrad Med J, 2019,26(2):69–79 |
[2] | Fabian ID, Onadim Z, Karaa E, et al. The management of retinoblastoma. Oncogene, 2018,37(12):1551–1560 |
[3] | Yun J, Li Y, Xu CT, et al. Epidemiology and Rb1 gene of retinoblastoma. Int J Ophthalmol, 2011,4(1):103–109 |
[4] | AlAli A, Kletke S, Gallie B, et al. Retinoblastoma for Pediatric Ophthalmologists. Asia Pac J Ophthalmol (Phila), 2018,7(3):160–168 |
[5] | Rao R, Honavar SG. Retinoblastoma. Indian J Pediatr, 2017,84(12):937–944 |
[6] | Zhu X, Xue L, Yao Y, et al. The FoxM1-ABCC4 axis mediates carboplatin resistance in human retinoblastoma Y-79 cells. Acta Biochim Biophys Sin (Shanghai), 2018,50(9):914–920 |
[7] | Fruci D, Cho WC, Nobili V, et al. Drug Transporters and Multiple Drug Resistance in Pediatric Solid Tumors. Curr Drug Metab, 2016,17(4):308–316 |
[8] | Kaltezioti V, Foskolou IP, Lavigne MD, et al. Prox1 inhibits neurite outgrowth during central nervous system development. Cell Mol Life Sci, 2021,78(7):3443–3465 |
[9] | Liu Y, Ye X, Zhang JB, et al. PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing beta-catenin expression and nuclear translocation. Oncogene, 2015,34(44):5524–5535 |
[10] | Foskolou IP, Stellas D, Rozani I, et al. Prox1 suppresses the proliferation of neuroblastoma cells via a dual action in p27-Kip1 and Cdc25A. Oncogene, 2013,32(8):947–960 |
[11] | Dadras SS, Skrzypek A, Nguyen L, et al. Prox-1 promotes invasion of kaposiform hemangioendotheliomas. J Invest Dermatol, 2008,128(12):2798–2806 |
[12] | Sasahira T, Ueda N, Yamamoto K, et al. Prox1 and FOXC2 act as regulators of lymphangiogenesis and angiogenesis in oral squamous cell carcinoma. PLoS One, 2014,9(3):e92534 |
[13] | Wang R, Sun Q, Wang P, et al. Notch and Wnt/beta-catenin signaling pathway play important roles in activating liver cancer stem cells. Oncotarget, 2016,7(5):5754–5768 |
[14] | Xiao W, Chen X, He M. Inhibition of the Jagged/Notch pathway inhibits retinoblastoma cell proliferation via suppressing the PI3K/Akt, Src, p38MAPK and Wnt/betacatenin signaling pathways. Mol Med Rep, 2014,10(1):453–458 |
[15] | Chen J, Yuan W, Wu L, et al. PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway. Oncotarget, 2017,8(6):9961–9973 |
[16] | Asnaghi L, Tripathy A, Yang Q, et al. Targeting Notch signaling as a novel therapy for retinoblastoma. Oncotarget, 2016,7(43):70028–70044 |
[17] | H?gstr?m J, Heino S, Kallio P, et al. Transcription Factor PROX1 Suppresses Notch Pathway Activation via the Nucleosome Remodeling and Deacetylase Complex in Colorectal Cancer Stem-like Cells. Cancer Res, 2018,78(20):5820–5832 |
[18] | Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature, 2012,481(7381):329–334 |
[19] | Hagiwara K, Ito H, Murate T, et al. PROX1 overexpression inhibits protein kinase C beta II transcription through promoter DNA methylation. Genes Chromosomes Cancer, 2012,51(11):1024–1036 |
[20] | Chang TM, Hung WC. The homeobox transcription factor Prox1 inhibits proliferation of hepatocellular carcinoma cells by inducing p53-dependent senescencelike phenotype. Cancer Biol Ther, 2013,14(3):222–229 |
[21] | Elsir T, Eriksson A, Orrego A, et al. Expression of PROX1 is a common feature of high-grade malignant astrocytic gliomas. J Neuropathol Exp Neurol, 2010, 69(2):129–138 |
[22] | Zhang Z, Zhou Z, Zhang M, et al. High Notch1 expression affects chemosensitivity of head and neck squamous cell carcinoma to paclitaxel and cisplatin treatment. Biomed Pharmacother, 2019,118:109306 |
[23] | Gao Y, Luo X, Zhang J. LincRNA-ROR is activated by H3K27 acetylation and induces EMT in retinoblastoma by acting as a sponge of miR-32 to activate the Notch signaling pathway. Cancer Gene Ther, 2021,28(1–2):42–54 |
[24] | Zang S, Chen F, Dai J, et al. RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity in human breast cancer. Oncol Rep, 2010,23(4):893–899 |
[25] | Li X, Yang L, Shuai T, et al. MiR-433 inhibits retinoblastoma malignancy by suppressing Notch1 and PAX6 expression. Biomed Pharmacother, 2016,82:247–255 |
/
〈 | 〉 |